ClinicalTrials.gg
CompletedNCT04564547Updated Jan 26, 2026Results posted

Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]

A Phase 2 interventional study of Islatravir and Ulonivirine in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 23 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
161
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized, controlled, double-blind, study to evaluate the safety and tolerability of islatravir (ISL) + ulonivirine based on review of the accumulated safety data, in adult participants with human immunodeficiency virus type 1 (HIV-1) who have been virologically suppressed for ≥6 months on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once-daily.

Read the detailed description

Based on laboratory findings of decreased lymphocyte and CD4+ T-cell counts across the islatravir program and as described in protocol amendment 2 (approved 01-Dec-2021), participants in study Part 1 (double-blind treatment period) were unblinded, discontinued all study interventions, and switched to standard of care non-study antiretroviral (ART) therapy. Participants who received ISL + ulonivirine (Groups 1 to 3) may have then entered into an unblinded safety monitoring period and were monitored for ≥6 months. As specified in protocol amendment 2, study Parts 2 and 3 were no longer planned or initiated for any participant.

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is -1 positive with plasma human immunodeficiency virus type 1 (HIV-1) RNA \<50 copies/mL at screening
  • Has been virologically suppressed on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for ≥6 months
  • Has a screening >200 cells/mm\^3 (completed by the central laboratory)
  • Is male or female, at least 18 years of age, at the time of signing the
  • Female participants are eligible to participate if not pregnant or breastfeeding, and at least one of the following conditions applies:

    • Is not a woman of (WOCBP)
    • Is a WOCBP and using a method that is highly effective (with a failure rate of \<1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis)

Exclusion criteria

Exclusion Criteria:

  • Has -2 infection
  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has active virus (HCV) coinfection (defined as detectable HCV RNA) or virus (HBV) coinfection (defined as hepatitis B surface antigen [HBsAg]-positive or HBV deoxyribonucleic acid [DNA] positive)
  • Has a current (active) diagnosis of acute hepatitis due to any cause
  • Has a history of ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
  • Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study
  • Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapies
  • Is currently participating in or has participated in a clinical study with an compound or device from 45 days prior to Day 1 through the study treatment period
  • Has a documented or known virological resistance to ulonivirine or nucleoside/nucleotide reverse transcriptase inhibitors (NNRTI)
  • Is female and expecting to conceive or donate eggs at any time during the study
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
161 participants (actual)

Study arms

  • Experimental
    Group 1: ISL 20 mg + Ulonivirine 100 mg

    Participants receive ISL 20 mg + ulonivirine 100 mg once weekly (QW) and placebo to BIC/FTC/TAF once daily (QD). Following study-wide discontinuation of study intervention, participants may have entered the optional unblinded safety monitoring period and received standard of care non-study ART.

    Drug: Islatravir · Drug: Ulonivirine · Drug: Placebo to Ulonivirine · Drug: Placebo to BIC/FTC/TAF

  • Experimental
    Group 2: ISL 20 mg + Ulonivirine 200 mg

    Participants receive ISL 20 mg + ulonivirine 200 mg QW and placebo to BIC/FTC/TAF QD. Following study-wide discontinuation of study intervention, participants may have entered the optional unblinded safety monitoring period and received standard of care non-study ART.

    Drug: Islatravir · Drug: Ulonivirine · Drug: Placebo to Ulonivirine · Drug: Placebo to BIC/FTC/TAF

  • Experimental
    Group 3: ISL 20 mg + Ulonivirine 400 mg

    Participants receive ISL 20 mg + ulonivirine 400 mg QW and placebo to BIC/FTC/TAF QD. Following study-wide discontinuation of study intervention, participants may have entered the optional unblinded safety monitoring period and received standard of care non-study ART.

    Drug: Islatravir · Drug: Ulonivirine · Drug: Placebo to BIC/FTC/TAF

  • Active comparator
    Group 4: BIC/FTC/TAF

    Participants receive placebo to ISL + placebo to ulonivirine QW and BIC/FTC/TAF 50 mg/200 mg/25 mg QD.

    Drug: BIC/FTC/TAF · Drug: Placebo to ISL · Drug: Placebo to Ulonivirine

Interventions

  • ISL capsule taken by mouth.

    Also known as: MK-8591

  • Ulonivirine tablet taken by mouth.

    Also known as: MK-8507

  • DrugBIC/FTC/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    BIC/FTC/TAF tablet taken by mouth.

    Also known as: BIKTARVY®

  • DrugPlacebo to ISL

    Placebo capsule matched to ISL taken by mouth.

  • DrugPlacebo to Ulonivirine

    Placebo tablet matched to ulonivirine taken by mouth.

  • DrugPlacebo to BIC/FTC/TAF

    Placebo tablet matched to BIC/FTC/TAF taken by mouth.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and supplemental statistical analysis plan (sSAP), presented here is the percentage of participants who experienced one or more AEs during the Double-blind Treatment Period and includes the 42 days following the final dose of double-blind study intervention.

    Time frame: Up to approximately 9 months

  2. Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who discontinued double-blind study intervention due to an AE during the Double-Blind Treatment Period.

    Time frame: Up to approximately 8 months

  3. Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who experienced one or more AEs during the Unblinded Safety Monitoring Period, beginning 42 days following the final dose of double-blind study intervention.

    Time frame: Up to approximately 37 months

07

Results

Posted Jan 26, 2026

Participant flow

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneGroup 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAF
Started40414040
Completed37393839
Not completed3221
Withdrew: Lost to follow-up0011
Withdrew: Physician decision0110
Withdrew: Withdrawal by subject3100
Unblinded Safety Monitoring Period
Participant flow — Unblinded Safety Monitoring Period
MilestoneGroup 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAF
Started3739370
Completed2525240
Not completed1214130
Withdrew: Lost to follow-up0110
Withdrew: Physician decision1010
Withdrew: Sponsor decision5640
Withdrew: Withdrawal by subject6770

Outcome measures

PrimaryPercentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and supplemental statistical analysis plan (sSAP), presented here is the percentage of participants who experienced one or more AEs during the Double-blind Treatment Period and includes the 42 days following the final dose of double-blind study intervention.

Time frame:
Up to approximately 9 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind
Percentage of ParticipantsGroup 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAF
Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind75.075.680.067.5
PrimaryPercentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who discontinued double-blind study intervention due to an AE during the Double-Blind Treatment Period.

Time frame:
Up to approximately 8 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period
Percentage of ParticipantsGroup 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAF
Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period0.04.92.50.0
PrimaryPercentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. As pre-specified in the protocol and sSAP, presented here is the percentage of participants who experienced one or more AEs during the Unblinded Safety Monitoring Period, beginning 42 days following the final dose of double-blind study intervention.

Time frame:
Up to approximately 37 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period
Percentage of ParticipantsGroup 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mg
Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period56.856.467.6

Adverse events

Collected over Up to approximately 46 months (Double-blind Treatment Period: AEs were assessed at the participant level for up to approximately 9 months [from randomization to 42 days after last double-blind study intervention]; Unblinded Safety Monitoring Period: AEs were assessed at the participant level for up to approximately 37 months [beginning 42 days after the final double-blind study intervention to last participant data collection]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ISL 20 mg + MK-8507 100 mg QW0/40 (0%)2/40 (5%)18/40 (45%)
ISL 20 mg + MK-8507 200 mg QW0/41 (0%)3/41 (7.3%)15/41 (36.6%)
ISL 20 mg + MK-8507 400 mg QW0/40 (0%)1/40 (2.5%)25/40 (62.5%)
BIC/FTC/TAF QD0/40 (0%)0/40 (0%)14/40 (35%)
ISL 20 mg + MK-8507 100 mg QW → Non-study ART0/37 (0%)0/37 (0%)8/37 (21.6%)
ISL 20 mg + MK-8507 200 mg QW → Non-study ART0/39 (0%)0/39 (0%)16/39 (41%)
ISL 20 mg + MK-8507 400 mg QW → Non-study ART0/37 (0%)1/37 (2.7%)16/37 (43.2%)
Most frequent serious events
Most frequent serious events
EventISL 20 mg + MK-8507 100 mg QWISL 20 mg + MK-8507 200 mg QWISL 20 mg + MK-8507 400 mg QWBIC/FTC/TAF QDISL 20 mg + MK-8507 100 mg QW → Non-study ARTISL 20 mg + MK-8507 200 mg QW → Non-study ARTISL 20 mg + MK-8507 400 mg QW → Non-study ART
Skin lacerationInjury, poisoning and procedural complications0/400/410/400/400/370/391/37
Device related thrombosisGeneral disorders1/400/410/400/400/370/390/37
Campylobacter gastroenteritisInfections and infestations1/400/410/400/400/370/390/37
CellulitisInfections and infestations1/400/410/400/400/370/390/37
Kaposi's sarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/400/411/400/400/370/390/37
Acute myocardial infarctionCardiac disorders0/401/410/400/400/370/390/37
Non-cardiac chest painGeneral disorders0/401/410/400/400/370/390/37
Renal colicRenal and urinary disorders0/401/410/400/400/370/390/37
Most frequent other events
Showing 10 of 18
Most frequent other events
EventISL 20 mg + MK-8507 100 mg QWISL 20 mg + MK-8507 200 mg QWISL 20 mg + MK-8507 400 mg QWBIC/FTC/TAF QDISL 20 mg + MK-8507 100 mg QW → Non-study ARTISL 20 mg + MK-8507 200 mg QW → Non-study ARTISL 20 mg + MK-8507 400 mg QW → Non-study ART
COVID-19Infections and infestations3/404/417/403/404/377/3911/37
DiarrhoeaGastrointestinal disorders1/403/416/400/402/372/390/37
FatigueGeneral disorders4/403/415/402/401/370/392/37
Accidental overdoseInjury, poisoning and procedural complications2/402/414/405/400/370/390/37
HeadacheNervous system disorders5/401/414/400/400/370/390/37
NauseaGastrointestinal disorders2/402/414/401/400/370/390/37
Back painMusculoskeletal and connective tissue disorders1/401/414/402/401/372/391/37
ConstipationGastrointestinal disorders1/400/413/402/400/370/391/37
NasopharyngitisInfections and infestations2/400/412/403/401/371/391/37
SinusitisInfections and infestations3/400/411/400/402/370/390/37

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Group 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAFTotal
Mean43.7 ± 12.146.5 ± 10.843.5 ± 12.647.9 ± 11.645.4 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAFTotal
Female986831
Male31333432130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAFTotal
Hispanic or Latino686828
Not Hispanic or Latino30303232124
Unknown or Not Reported43209
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: ISL 20 mg + Ulonivirine 100 mgGroup 2: ISL 20 mg + Ulonivirine 200 mgGroup 3: ISL 20 mg + Ulonivirine 400 mgGroup 4: BIC/FTC/TAFTotal
American Indian or Alaska Native20002
Asian02013
Native Hawaiian or Other Pacific Islander00000
Black or African American1014131350
White27242726104
More than one race10001
Unknown or Not Reported01001
08

Study locations

23 sites
  • Pueblo Family Physicians ( Site 2702)
    Phoenix, Arizona 85015, United States
  • Men's Health Foundation ( Site 2710)
    Los Angeles, California 90069, United States
  • Midway Immunology and Research ( Site 2713)
    Ft. Pierce, Florida 34982, United States
  • Triple O Research Institute, P.A. ( Site 2712)
    West Palm Beach, Florida 33407, United States
  • Infectious Disease Specialists Of Atlanta PC ( Site 2704)
    Decatur, Georgia 30033, United States
  • Chatham County Health Department ( Site 2707)
    Savannah, Georgia 31410, United States
  • Kansas City CARE Clinic ( Site 2703)
    Kansas City, Missouri 64111, United States
  • Saint Hope Foundation, Inc. ( Site 2716)
    Bellaire, Texas 77401, United States
  • Texas Centers for Infectious Disease Associates P.A. ( Site 2709)
    Fort Worth, Texas 76104, United States
  • DCOL Center for Clinical Research ( Site 2715)
    Longview, Texas 75605, United States
  • CHU de Toulouse - Hopital Purpan ( Site 2302)
    Toulouse, Haute-Garonne 31059, France
  • Hopital Gui de Chauliac. ( Site 2303)
    Montpellier, Herault 34295, France
  • CHU Hotel Dieu Nantes ( Site 2310)
    Nantes, Loire-Atlantique 44093, France
  • Centre Hospitalier Regional du Orleans ( Site 2304)
    Orléans, Loiret 45100, France
  • Hopital Avicenne ( Site 2305)
    Bobigny, Seine-Saint-Denis 93000, France
  • Hopital Saint Louis ( Site 2308)
    Paris, 75010, France
  • Hopital Saint-Antoine ( Site 2307)
    Paris, 75012, France
  • Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 2306)
    Paris, Île-de-France Region 75013, France
  • Universitaetsspital Zuerich ( Site 2601)
    Zuerich, Canton of Aargau 8091, Switzerland
  • Universitaetsspital Basel ( Site 2602)
    Basel, Canton of Basel-City 4031, Switzerland
  • Inselspital Universitaetsspital Bern ( Site 2603)
    Bern, Canton of Bern 3010, Switzerland
  • Hopitaux Universitaires de Geneve HUG ( Site 2604)
    Geneva, Canton of Geneva 1211, Switzerland
  • CHUV (centre hospitalier universitaire vaudois) ( Site 2605)
    Lausanne, Canton of Vaud 1011, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jan 2025, 46 months.

Results were first posted in Jan 2026, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2020
First posted
Sep 25, 2020
StartActual
Mar 9, 2021
Primary completionActual
Jan 30, 2025
CompletionActual
Jan 30, 2025
Results first posted
Jan 26, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04564547
Responsible party
Sponsor
First posted
Sep 25, 2020
Start date
Mar 9, 2021
Primary completion
Jan 30, 2025
Completion
Jan 30, 2025
Results posted
Jan 26, 2026
Last update
Jan 26, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Islatravir · Ulonivirine

Start the discussion